New cancer drug enters human testing: can it shrink tough tumors?

NCT ID NCT06639256

Recruiting now Disease control Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

Summary

This early-stage clinical trial is testing a new drug called HY07121 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose, understand how the body processes the drug, and see if it shows any early signs of shrinking tumors. The study will enroll about 258 adults to first determine the best dose and then see how well that dose works.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TOLERABILITY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Cancer Hospital of Shandong First Medical University
RECRUITING

Jinan, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

EFFICACY SAFETY TOLERABILITY